Exanta

 

Drug Name: Exanta (ximelagatran) 36 mg bid oral formulation Indication(s): reduction of risk of stroke or systemic embolic events… (More)

INTRODUCTION The effect of the oral direct thrombin inhibitor (DTI) ximelagatran (Exanta, AstraZeneca) on the endogenous thrombin… (More)

Ximelagatran (Exanta, AstraZeneca) is a novel oral direct thrombin inhibitor that inhibits the final step in the coagulation… (More)

Patients who undergo orthopaedic surgery are at substantially increased risk for venous thromboembolic events. These include… (More)

The phase III trial EXPRESS was a randomised, double-blind comparison of two anticoagulant therapies used as prophylaxis against… (More)

Two new classes of anticoagulants in development at the present time [anti-factor Xa and anti-factor IIa (direct antithrombin… (More)

Ximelagatran (Exanta, AstraZeneca) is a novel, oral direct thrombin inhibitor (oral DTI) that is rapidly converted to melagatran… (More)

There are many well-known drawbacks associated with the currently used antithrombotic agents, warfarin, heparin, and low… (More)

The oral direct thrombin inhibitor (oral DTI) ximelagatran (Exanta, AstraZeneca) is rapidly absorbed and bioconverted to its… (More)